GlycoMimetics GMI-1359 Data Selected for Presentation at 63rd American Society of Hematology (ASH) Annual Meeting and ExpositionBusiness Wire • 11/11/21
GlycoMimetics, Inc. (GLYC) CEO Harout Semerjian on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/02/21
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2021Business Wire • 11/02/21
Efficacy and Safety Data for GlycoMimetics' Lead Investigational Drug Uproleselan Published in BLOODBusiness Wire • 09/23/21
GlycoMimetics to Present at Upcoming H.C. Wainwright & Co Annual Global Investment Virtual ConferenceBusiness Wire • 09/08/21
Implied Volatility Surging for GlycoMimetics (GLYC) Stock OptionsZacks Investment Research • 08/23/21
GlycoMimetics, Inc. (GLYC) CEO Rachel King on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/08/21
GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2021Business Wire • 08/05/21
GlycoMimetics Names Harout Semerjian as New Chief Executive Officer to Succeed Retiring CEO Rachel KingBusiness Wire • 08/04/21
Trial Launches to Evaluate GlycoMimetics' Uproleselan Added to Cladribine Plus Low-Dose Cytarabine in AML PatientsBusiness Wire • 07/22/21
GlycoMimetics Announces Initiation of Clinical Trial Evaluating Uproleselan in Combination With Venetoclax and AzacitidineBusiness Wire • 07/12/21
GlycoMimetics Announces Investigator-Sponsored Phase 2 Clinical Trial Evaluating Uproleselan for Prevention of Gastro-Intestinal Toxicity in Autologous Hematopoietic Cell TransplantationBusiness Wire • 05/26/21
GlycoMimetics, Inc. (GLYC) CEO Rachel King on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/03/21
GlycoMimetics Reports Highlights and Financial Results for First Quarter 2021Business Wire • 05/03/21
Positive Findings From Phase 1b Trial of GlycoMimetics' GMI-1359 To Be Presented at AACR 2021 MeetingBusiness Wire • 04/10/21
GlycoMimetics to Present at AACR 2021 Meeting on Positive Therapeutic Effects of GMI-1757 in a Pancreatic Adenocarcinoma ModelBusiness Wire • 04/10/21
GlycoMimetics to Share GMI-1359 and Galectin-3 Antagonist Program Data at AACR 2021 MeetingBusiness Wire • 03/10/21
Apollomics, Inc Doses First Patient in Phase 1 Clinical Trial in China of GlycoMimetics' Uproleselan for the Treatment of AMLBusiness Wire • 03/04/21